Inclusion Criteria:~1. Diagnosis of probable Alzheimer's disease (AD) of mild to moderate severity (as
determined by a Mini Mental State Examination (MMSE) score of 14 - 26 inclusive).~2. Ability to give informed
consent, designate a decision-maker or have an already recognized decision-maker (such as a legal guardian or
health care proxy).~3. Ability to comply with testing and infusion regimen.~4. An able caregiver willing to
participate (such as a spouse, child, other relative, close friend, aide or other professional caregiver
closely involved in helping the patient take care of himself/herself).~5. Venous access suitable for repeated
infusion and phlebotomy.~6. On stable doses of approved AD medications for at least 3 months.~7. As applicable,
on stable doses of psychoactive medications (e.g. antidepressants, antipsychotics) for at least 6 weeks.~8.
Neuroimaging performed after symptom onset consistent with the patient's diagnosis.~9. Clinical laboratory
values within normal limits or if abnormal, judged clinically insignificant by the Principal Investigator.~10.
Women who want to take part in this study must either be post-menopausal, surgically sterilized or agree to
avoid becoming pregnant during the entire period of their participation in this study.~
